Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

Makoto Chuma(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Katsuaki Ogushi(Yokohama City University Medical Center), Hidenori Toyoda(Ogaki Municipal Hospital), Nobuhiro Hattori(St. Marianna University School of Medicine), Kazushi Numata(Yokohama City University Medical Center), Makoto Kako(Shonan Kamakura General Hospital), Atsushi Hiraoka(Ehime Prefectural Central Hospital), Takahide Nakazawa(Kitasato University Hospital), Takashi Kumada(Gifu Kyoritsu University), Hiroyuki Fukuda(Yokohama City University Medical Center), Kojiro Michitaka(Ehime Prefectural Central Hospital), Naohisa Wada(Kitasato University), Toshifumi Tada(Himeji Red Cross Hospital), Shuitirou Iwasaki(Kitasato University), Shuhei Nishigori(Yokohama Minami Kyosai Hospital), Akito Nozaki(Yokohama City University Medical Center), Tatehiro Kagawa(Tokai University), Shunji Hirose(Tokai University), Masanori Atsukawa(Nippon Medical School), Haruki Uojima(National Center for Global Health and Medicine), Yuki Miura(Japanese Red Cross Hadano Hospital), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Satoshi Hishiki(Saiseikai Ibaraki Hospital), Norio Itokawa(Chiba Hokusou Hospital), Taeang Arai(Nippon Medical School), Hisashi Hidaka(Kitasato University)
Cancers
January 26, 2020
Cited by 54


Related Papers